Related Experiment Video
Updated: May 20, 2026
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Modeling the inhibition of breast cancer growth by GM-CSF
Barbara Szomolay1, Tim D Eubank, Ryan D Roberts
1Mathematical Biosciences Institute, The Ohio State University, USA. b.szomolay@warwick.ac.uk
Abstract:
M-CSF is overexpressed in breast cancer and is known to stimulate macrophages to produce VEGF resulting in angiogenesis. It has recently been shown that the growth factor GM-CSF injected into murine breast tumors slowed tumor growth by secreting soluble VEGF receptor-1 (sVEGFR-1) that binds and inactivates VEGF. This study presents a mathematical model that includes all the components above, as well as MCP-1, tumor cells, and oxygen. The model simulations are representative of the in vivo data through predictions of tumor growth using different protocol strategies for GM-CSF for the purpose of predicting higher degrees of treatment success. For example, our model predicts that once a week dosing of GM-CSF would be less effective than daily, twice a week, or three times a week treatment because of the presence of essential factors required for the anti-tumor effect of GM-CSF.
Insights
Granulocyte-macrophage colony-stimulating factor (GM-CSF) can slow breast tumor growth by inhibiting VEGF. Mathematical modeling suggests that frequent GM-CSF administration enhances its anti-tumor efficacy.
Area of Science:
- Oncology
- Immunology
- Mathematical Biology
Background:
- Macrophage colony-stimulating factor (M-CSF) is overexpressed in breast cancer, promoting tumor growth via VEGF-induced angiogenesis.
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown potential in slowing tumor growth by inducing soluble VEGF receptor-1 (sVEGFR-1), which neutralizes VEGF.
Purpose of the Study:
- To develop a mathematical model integrating M-CSF, GM-CSF, VEGF, sVEGFR-1, MCP-1, tumor cells, and oxygen.
- To simulate tumor growth dynamics and evaluate different GM-CSF treatment protocols for optimizing anti-tumor effects.
Main Methods:
- Development of a comprehensive mathematical model incorporating key biological components and their interactions.
- In silico simulations to predict tumor growth under various GM-CSF dosing frequencies.
Main Results:
- Model simulations accurately reflect in vivo data, demonstrating GM-CSF's anti-tumor capabilities.
- Predictions indicate that less frequent GM-CSF administration (e.g., once weekly) is less effective than more frequent schedules (daily, twice, or thrice weekly).
Conclusions:
- Mathematical modeling provides a valuable tool for predicting the efficacy of GM-CSF immunotherapy in breast cancer.
- Optimized GM-CSF dosing strategies, particularly more frequent administration, are crucial for maximizing anti-tumor responses and treatment success.
